3M (MMM) Reports July 17 — Turnaround Story or Value Trap? Here’s What the Data Says
3M Company (NYSE: MMM) reports Q2 2026 earnings on July 17 with analysts expecting $2.26 EPS on $6.39B in revenue. After years of litigation chaos, a massive healthcare spinoff, and over $15 billion in legal settlements, the company has spent the last 18 months quietly rebuilding. The question heading into Thursday: is the turnaround real, or is the stock pricing in a recovery that hasn’t fully arrived? We ran MMM through Ask The Desk to find out.
The Setup: What Happened to 3M
To understand where MMM stands today, you need to understand what happened to it. Between 2022 and 2023, the company absorbed two catastrophic legal liabilities simultaneously — the Combat Arms earplug litigation and PFAS water contamination settlements — resulting in a staggering GAAP net loss of -$6.99 billion in FY2023. At the same time, 3M spun off its healthcare division as Solventum, reducing annual revenue from the $34-35B range down to approximately $25B.
On paper, this looks like a company in freefall. In reality, it may be the opposite — a company that took all of its pain at once and is now operating with those liabilities largely in the rearview mirror.
The Earnings Beat Cadence — Management Has Credibility Back
One of the clearest signals in the data is the consistency of earnings beats since the restructuring began:
| Quarter | EPS Actual | EPS Estimate | Result |
|---|---|---|---|
| Q1 2026 | $2.14 | $1.98 | Beat +8.1% |
| Q4 2025 | $1.83 | $1.80 | Beat |
| Q3 2025 | $2.19 | $2.07 | Beat |
| Q2 2025 | $2.16 | $2.01 | Beat |
Four consecutive quarters of EPS beats is not an accident — it signals that management has re-established operational discipline and is setting realistic expectations with the Street. Going into July 17, consensus sits at $2.26 EPS. A fifth consecutive beat would be a meaningful positive signal for the turnaround thesis.
The Financials: What’s Working and What Isn’t
What’s Working:
- Operating margin: 18.3% — strong for a diversified industrial, supported by $1.3B+ in restructuring savings
- ROIC: 11.5% — recovering from a 7.8% trough in FY2023, now above cost of capital
- Interest expense dropped $462M year-over-year — a direct result of debt paydown post-settlement, one of the clearest signs the financial cleanup is working
- Share buybacks resumed — diluted shares fell from 552M to 539M in FY2025, confirming capital allocation discipline is back
- Debt/equity improved from 3.56x (FY2024) to 2.75x (FY2025) — still elevated but moving in the right direction
What’s Not Working:
- FCF quality remains the biggest concern — FY2025 free cash flow of $1.40B on a P/FCF of 61.3x is difficult to justify, even in a recovery story
- Revenue growth of just 1.5% — unexciting; the market needs to see 2%+ organic growth to believe the remaining portfolio can compound
- Gross margin slipped from 41.0% (FY2024) to 39.6% (FY2025) — early warning sign on pricing and cost pressure
- Negative operating leverage of -4.92 — costs are rising slightly faster than revenues at the margin; this needs to reverse
The Litigation Question — Is It Actually Behind Them?
This is the central debate. The bear camp argues the balance sheet still shows the scars — $12.94B in total debt, $7.70B in net debt, and a debt/equity ratio of 2.75x. The bull camp argues those are known, funded liabilities that are now in paydown mode, not new risks.
The data supports the bull camp on this specific point. Interest expense dropped from $1.18B in FY2024 to $720M in FY2025 — a $462M annual improvement that flows directly to earnings. Interest coverage improved from 4.17x to 6.34x. The debt payback period of 9.27 years is stretched, but the direction of travel is clearly positive.
The Altman Z-Score of 4.19 places MMM firmly in the “safe” zone — no near-term financial distress risk despite the leverage. This is not a company on the edge; it’s a company cleaning up a mess on a defined timeline.
Valuation — Fair, Not Cheap
| Metric | Value | Assessment |
|---|---|---|
| P/E (TTM) | 26.5x | Fair for quality industrial |
| EV/EBITDA | 15.9x | Slightly above peers (12-14x typical) |
| P/FCF | 61.3x | Expensive — biggest valuation risk |
| Price/Sales | 3.4x | Reasonable given 18%+ operating margins |
| Dividend Yield | 1.37% | Conservative; payout ratio 36% |
The P/FCF of 61.3x is the number that keeps value investors away. It’s high because FCF is still suppressed from settlement cash outflows — not because the underlying business is weak. If FCF normalizes toward the $3-4B range management has guided toward, the P/FCF compresses rapidly. That normalization is the entire bull thesis in one number.
What to Watch on July 17
Four numbers will determine how the stock trades after the report:
- Organic revenue growth — the market wants 2%+. Below 1% reads as stagnation in the remaining portfolio.
- Full-year EPS guidance — consensus is in the $8.80-$9.00 range. A raise confirms management confidence.
- FCF update — full-year FCF guidance is critical. The gap between GAAP and adjusted FCF needs to narrow.
- Gross margin — any further deterioration from 39.6% flags a structural cost problem, not just a transition-year issue.
Bull vs. Bear — The 12-Month Case
Bull Case:
- Litigation is a sunk cost; earnings power of ~$9 EPS on a clean run-rate basis is achievable in FY2026
- ROIC recovering toward 12-13% signals genuine operational improvement
- At ~$160, the stock trades at approximately 18x forward earnings — reasonable for a high-quality diversified industrial
- FCF normalization toward $3-4B would drop the P/FCF from 61x to a reasonable 13-18x range
Bear Case:
- P/FCF of 61x leaves zero margin of safety if execution slips
- Revenue growth of 1.5% with negative gross profit growth is not a growth story
- Debt/equity of 2.75x limits flexibility if the macro deteriorates
- The company is structurally smaller post-Solventum and hasn’t yet proven the remaining portfolio can accelerate
The Verdict
MMM is more turnaround than value trap — but the thesis requires continued execution and patience. The litigation that nearly broke the company is largely resolved. ROIC, interest coverage, and operating margins are all moving in the right direction. The four-quarter EPS beat cadence is real.
But the stock is not cheap. A P/FCF of 61x prices in a clean FCF recovery that hasn’t fully arrived yet. July 17 is a critical checkpoint — a beat plus raised guidance extends the turnaround credibility and likely pushes the stock higher. A miss on revenue growth or FCF guidance reopens the value trap debate immediately.
The smart play: Watch the open on July 17 post-earnings. If MMM beats and raises, the data supports the turnaround. If it misses on revenue or FCF, the elevated valuation provides little downside cushion.
This analysis was researched using Ask The Desk, In2Trading’s AI-powered stock analysis platform. Ask The Desk delivers institutional-quality fundamental and technical analysis on any ticker in seconds — built for self-directed investors who want real data, not headlines.
Financial disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decisions.